Use of SCF and G-CSF in the treatment of cerebral ischemia and neurological disorders

a technology of cerebral ischemia and gcsf, which is applied in the direction of peptide/protein ingredients, metabolism disorders, peptide sources, etc., can solve the problems of rapid death of neurons and vascular structures in the supplied region of the brain, long-term disability, and severe disability, and achieve the effect of affecting body weigh

Inactive Publication Date: 2006-07-13
NORTHWESTERN UNIV
View PDF21 Cites 17 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0109] To determine whether treatment with SCF and G-CSF, alone or in combination, significantly affect body

Problems solved by technology

Stroke is the third leading cause of death in the U.S., and it can lead to severe, long-term disability.
Damage to the brain can cause loss of speech, vision, or movement in an arm or a leg, depending on the part of the brain that is affected.
Cerebral ischemia induced by stroke leads to rapid death of neurons and vascular structures in the supplied region of the brain.
The loss of neurons, arterioles, and capillaries in the infarcted zone i

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1

SCF and G-CSF Administration Improves Neurological Function in a Limb Placement Test in a Rat Model of Stroke

[0102] To determine whether treatment with the cytokines, SCF and G-CSF, alone or in combination, improves functional outcome after stroke, rats were subject to experimental stroke and examined for neurological function improvement after cytokine treatment post-stroke. Rats were subject to anesthesia (methohexital sodium, 50 mg / kg, intraperitoneally, Monarch Pharmaceuticals) and permanent ligation / occlusion of the right middle cerebral artery, distal to the striatal branch, and ligation of the ipsilateral common carotid artery. Three hours post-ischemia, rats were treated with SCF and G-CSF and subjected to a limb-placement test for the evaluation of neurological deficits.

[0103] After induction of cerebral ischemia, adult male spontaneously hypertensive rats (250-350 g) were randomly divided into four experimental groups as follows: 1) control (saline only; n=10); 2) SCF (n...

example 2

SCF and G-CSF Administration Improve Neurological Function in a Foot-Fault Test in a Rat Model of Stroke

[0106] In another test to determine whether the administration of SCF and G-CSF, alone or in combination, at three hours after cerebral ischemia, improves functional outcome after stroke, ischemic rats were subjected to a foot-fault test and evaluated for improvements in neurological function.

[0107] As set out in Example 1, rats were randomly divided into the same four experimental groups and given the same treatments. Neurological deficits were evaluated using the foot-fault test (10 foot faults in 10 steps=severe neurological deficits; no foot faults=no neurological deficits). The test was performed blindly before administration of the aforementioned cytokines, and at one, four, seven, and ten weeks after the final injections of the cytokines. SCF treatment caused significant neurological functional improvement as early as one week after cytokine treatment when compared with c...

example 3

The Effect of SCF and G-CSF Administration on Body Weight

[0109] To determine whether treatment with SCF and G-CSF, alone or in combination, significantly affect body weight, rat body weights were measured before MCAO and at one, four, and seven weeks post-cytokine treatments.

[0110] As set out in Example 1, rats were randomly divided into the same four experimental groups and given the same treatments. Rats that received G-CSF alone showed a significant reduction in body weight at one week post-cytokine administration compared to all other groups (p<0.01). However, by four weeks post-treatment, the lost body weight was regained and there were no significant differences in body weight between any of the treatment groups throughout the remainder of the experiments. SCF and SCF+G-CSF treatments did not have any effect on body weight.

[0111] This example illustrates that treatment with G-CSF causes a transient reduction in body weight early after treatment, but no significant differenc...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Volumeaaaaaaaaaa
Plasticityaaaaaaaaaa
Toxicityaaaaaaaaaa
Login to view more

Abstract

The present invention relates to the use of stem cell factor (SCF) polypeptide, alone and in combination with granulocyte colony stimulating factor (G-CSF) polypeptide, in the prevention or treatment of injury to the brain after cerebral ischemia or neurological disorder. More particularly, the invention provides methods of improving neurological function and outcome after stroke by the administration of SCF polypeptide, alone and in combination with G-CSF polypeptide. This treatment can be used alone or in combination with other well-known methods of treatment of cerebral ischemia and neurological disorders in a mammal.

Description

RELATED APPLICATIONS [0001] This application claims benefit of U.S. Provisional Patent Application Ser. No. 60 / 625,189 filed Nov. 5, 2004, which is incorporated herein by reference in its entirety.FIELD OF THE INVENTION [0002] The present invention relates to the use of stem cell factor (SCF) polypeptide, alone and in combination with granulocyte colony stimulating factor (G-CSF) polypeptide, to prevent or repair injury to the brain resulting from cerebral ischemia and neurological disorders. More particularly, the invention provides methods of treating stroke by the administration of SCF polypeptide, alone and in combination with G-CSF polypeptide, to improve functional recovery in both acute and chronic stages of stroke. BACKGROUND OF THE INVENTION [0003] Stroke is the leading cause of adult disability and the third cause of death worldwide. In the United States alone, a person has a stroke every 45 seconds, which accounts for approximately 700,000 people per year. Stroke is the t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K38/19A61K38/18
CPCA61K38/18A61K38/193A61K2300/00A61K38/30A61P25/00A61P25/28
Inventor ZHAO, LI-RUKESSLER, JOHNSINGHAL, SEEMAJAYESH, MEHTA
Owner NORTHWESTERN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap